Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Tulisokibart Biologics Sequence Review Report 2026: TL1A Similarity and Patent-Risk Signals
Latest Hotspot
6 min read
Tulisokibart Biologics Sequence Review Report 2026: TL1A Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tulisokibart, an antibody targeting TL1A.
Read →
Suvemcitug Biologics Sequence Review Report 2026: VEGF-A Similarity and Patent-Risk Signals
Latest Hotspot
6 min read
Suvemcitug Biologics Sequence Review Report 2026: VEGF-A Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Suvemcitug, an antibody targeting VEGF-A.
Read →
Riliprubart Biologics Sequence Review Report 2026: C1s Similarity and Patent-Risk Signals
Latest Hotspot
6 min read
Riliprubart Biologics Sequence Review Report 2026: C1s Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Riliprubart, an antibody targeting C1s.
Read →
Rademikibart Biologics Sequence Review Report 2026: IL-4Ralpha Similarity and Patent-Risk Signals
Latest Hotspot
6 min read
Rademikibart Biologics Sequence Review Report 2026: IL-4Ralpha Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rademikibart, an antibody targeting IL-4Ralpha.
Read →
Nisevokitug Biologics Sequence Review Report 2026: TGF-beta1 Similarity and Patent-Risk Signals
Latest Hotspot
6 min read
Nisevokitug Biologics Sequence Review Report 2026: TGF-beta1 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nisevokitug, an antibody targeting TGF-beta1.
Read →
Mevonlerbart Biologics Sequence Review Report 2026: Fel d 1 Similarity and Patent-Risk Signals
Latest Hotspot
6 min read
Mevonlerbart Biologics Sequence Review Report 2026: Fel d 1 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Mevonlerbart, an antibody targeting Fel d 1.
Read →
Gotistobart Biologics Sequence Review Report 2026: CTLA-4 Similarity and Patent-Risk Signals
Latest Hotspot
6 min read
Gotistobart Biologics Sequence Review Report 2026: CTLA-4 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Gotistobart, an antibody targeting CTLA-4.
Read →
Freneslerbart Biologics Sequence Review Report 2026: Fel d 1 Similarity and Patent-Risk Signals
Latest Hotspot
6 min read
Freneslerbart Biologics Sequence Review Report 2026: Fel d 1 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Freneslerbart, an antibody targeting Fel d 1.
Read →
Ersodetug Biologics Sequence Review Report 2026: Insulin receptor Similarity and Patent-Risk Signals
Latest Hotspot
6 min read
Ersodetug Biologics Sequence Review Report 2026: Insulin receptor Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ersodetug, an antibody targeting Insulin receptor.
Read →
Empasiprubart Biologics Sequence Review Report 2026: C2 Similarity and Patent-Risk Signals
Latest Hotspot
6 min read
Empasiprubart Biologics Sequence Review Report 2026: C2 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Empasiprubart, an antibody targeting C2.
Read →
Denecimig Biologics Sequence Review Report 2026: Factor IX × Factor X Similarity and Patent-Risk Signals
Latest Hotspot
6 min read
Denecimig Biologics Sequence Review Report 2026: Factor IX × Factor X Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Denecimig, an antibody targeting Factor IX × Factor X.
Read →
Delpacibart Biologics Sequence Review Report 2026: CD71 Similarity and Patent-Risk Signals
Latest Hotspot
6 min read
Delpacibart Biologics Sequence Review Report 2026: CD71 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Delpacibart, an antibody targeting CD71.
Read →